Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Heath, Paul T., Galiza, Eva P., Baxter, David N., Boffito, Marta, Browne, Duncan, Burns, Fiona, Chadwick, David R., Clark, Rebecca, Cosgrove, Catherine, Galloway, James, Goodman, Anna L., Heer, Amardeep, Higham, Andrew, Iyengar, Shalini, Jamal, Arham, Jeanes, Christopher, Kalra, Philip A., Kyriakidou, Christina, McAuley, Daniel F., Meyrick, Agnieszka, Minassian, Angela M., Minton, Jane, Moore, Patrick, Munsoor, Imrozia, Nicholls, Helen, Osanlou, Orod, Packham, Jonathan, Pretswell, Carol H., San Francisco Ramos, Alberto, Saralaya, Dinesh, Sheridan, Ray P., Smith, Richard, Soiza, Roy L., Swift, Pauline A., Thomson, Emma C., Turner, Jeremy, Viljoen, Marianne E., Albert, Gary, Cho, Iksung, Dubovsky, Filip, Glenn, Greg, Rivers, Joy, Robertson, Andreana, Smith, Kathy, Toback, Seth
Format: Artigo
Idioma:Inglês
Publicat: Massachusetts Medical Society 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262625/
https://ncbi.nlm.nih.gov/pubmed/34192426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107659
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars